Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
The goal of this clinical research study is to learn if adding the combination of abiraterone
 acetate and prednisone with or without enzalutamide to hormonal therapy can help to control
 prostate cancer when given before surgery. The safety of the drug combination will also be
 studied.
Study Groups:

 If you are found to be eligible to take part in this study, you will be randomly assigned
 (like the roll of dice) to 1 of 2 groups. You will have a 2 out of 3 chance of being assigned
 to Group A and a 1 out of 3 chance of being assigned to Group B.

 If you are in Group A, you will receive hormonal therapy (LHRH), abiraterone acetate,
 prednisone, and enzalutamide.

 If you are in Group B, you will receive LHRH, abiraterone acetate, and prednisone.

 Study Drug Administration:

 The study doctor will decide what hormone therapy you will receive, will explain when and how
 you should take it, and explain any risks.

 In addition, you will take 4 abiraterone acetate tablets by mouth each day (all at the same
 time) at least 1 hour before a meal or 2 hours after a meal. You will also take 1 tablet of
 prednisone by mouth 1 time each day to help lower the risk of side effects caused by
 abiraterone acetate.

 If you are in Group A, you will also take 4 capsules of enzalutamide by mouth each day. You
 should take enzalutamide at about the same time every morning. Enzalutamide can be taken with
 or without food. If you miss a dose, you should NOT take another dose until the next day. You
 should tell the study doctor as soon as possible if you miss a dose.

 About every 28-days is called a cycle. You should return all unused study drug and/or empty
 pill bottles at the end of each cycle.

 Study Visits:

 On Day 1 of Cycle 1:

 -  You will have a physical exam.

 -  Blood (about 3-4 tablespoons) will be drawn for routine tests and to check your
 prostatic specific antigen (PSA) level.

 On Day 15 of Cycles 1, 2 and 3, blood (about 2 tablespoons) will be drawn to check your liver
 function. These tests may be done at your local doctor's office and the results faxed to MD
 Anderson.

 On Day 1 of Cycles 2, 3, 4, 5 and 6:

 -  You will have a physical exam.

 -  Blood (about 3-4 tablespoons) will be drawn for routine tests. This blood will also be
 used to check your PSA level.

 The testing on Cycles 2, 4 and 6 may be done at your local doctor's office and the results
 faxed to MD Anderson.

 Within 14 days before surgery and at your End of Treatment Visit:

 -  You will have a physical exam.

 -  Blood (about 3-4 tablespoons) and urine will be collected for routine tests. This blood
 will also be used to check your PSA level, your blood sugar levels, and blood-clotting
 function. You will be asked to fast for at least 8 hours before these blood draws.

 -  You will have a chest x-ray or a CT scan of the chest.

 -  You will have an EKG to check your heart function.

 Surgery:

 After 6 cycles of study treatment, you will have surgery to remove your prostate. You will be
 asked to sign a separate consent form for this surgery, and the risks will be discussed with
 you. Your leftover prostate gland tissue from surgery will be collected and used for
 biomarker testing.

 About 4 to 8 weeks after your surgery:

 -  You will have a physical exam.

 -  Blood (about 3-4 tablespoons) drawn for routine tests. This blood will also be used to
 check your PSA, testosterone, cholesterol, and blood sugar levels.

 Length of Study:

 You may receive the study drugs for about 6 months. You will be taken off study early if the
 disease gets worse, if you have intolerable side effects, or if your study doctor thinks it
 is in your best interest to stop, or of you are unable to follow study directions.

 Your participation on the study will be over once you have completed the visits after
 surgery.

 This is an investigational study. Abiraterone acetate is FDA approved in combination with
 prednisone for the treatment of patients with metastatic castration-resistant prostate cancer
 who have received prior chemotherapy containing docetaxel. Prednisone is FDA approved and
 commercially available as a corticosteroid. Enzalutamide is FDA approved and commercially
 available for the treatment of certain types of prostate cancer. Their combination with
 hormone therapy in patients with prostate cancer is investigational.

 Up to 69 patients will be enrolled in this study. All will be enrolled at MD Anderson.
Inclusion Criteria:

 1. Be willing/able to adhere to the prohibitions and restrictions specified in this
 protocol

 2. Have signed an informed consent document indicating that the subjects understand the
 purpose of and procedures required for the study and are willing to participate in the
 study

 3. Written Authorization for Use and Release of Health and Research Study Information has
 been obtained.

 4. Male age >/=18 years.

 5. Histologically or cytologically confirmed adenocarcinoma of the prostate with no
 histological variants (such as small cell, sarcomatoid, pure ductal cancer,
 transitional cell carcinoma).

 6. Pathology review at treating academic institution or member institution (Note: if
 patient's prostate biopsy was not read at the treating institution, it must be
 reviewed at the study site to confirm eligibility).

 7. At least three core biopsies involved with cancer (a minimum of 6 core biopsies must
 be obtained at baseline). A prostate biopsy within 3 months from screening is allowed
 for entry requirements. Patients must have a Gleason score > 5 (total).

 8. At least one of the following features: a) PSA > 10 ng/ml; b) PSA velocity > 2
 ng/ml/year (defined as a rise in PSA of > 2 ng/ml in the preceding 12 month period);
 c) Gleason score >/= 7; d) Gleason score 6 if either PSA >/= 10 ng/ml or PSA velocity
 >/=2 ng/ml/year

 9. Serum testosterone >200 ng/dL. For patients treated with up to 1 month of LHRH
 agonist, a testosterone measurement prior to the LHRH treatment will be used to
 determine eligibility, and must have been > 200 ng/dL.

 10. Urologist must agree that patient is suitable for prostatectomy.

 11. No evidence of metastatic disease as determined by imaging procedures.

 12. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

 13. Hemoglobin >/= 10.0 g/dL independent of transfusion.

 14. Platelet count >/=100,000/µL.

 15. Patients should have adequate bone marrow function defined as an absolute peripheral
 neutrophil count (ANC) >/= 1,500.

 16. Creatinine clearance >/= 60 mL/min

 17. Serum potassium >/= 3.5 mmol/L.

 18. Serum albumin >/= 3.5 g/dL.

 19. Liver function test with serum bilirubin </= 1.5x upper limit of normal (ULN) and ALT
 and AST </= 1.5x ULN.

 20. Able to swallow the study drug whole as a tablet.

 21. Patients must have normal coagulation profile and no history of substantial non-
 iatrogenic bleeding diathesis.

 22. Agree to use a double-barrier method of contraception which involves the use of a
 condom in combination with one of the following: contraceptive sponge, diaphragm, or
 cervical ring with spermicidal gel or foam, if having sex with a woman of
 child-bearing potential during the length of the study and for one week after
 abiraterone is discontinued and for at least three months after enzalutamide is
 discontinued.

 23. Willing to take abiraterone acetate on an empty stomach; no food should be consumed at
 least two hours before and for at least one hour after the dose of abiraterone acetate
 is taken.

 Exclusion Criteria:

 1. Serious or uncontrolled co-existent non-malignant disease, including active and
 uncontrolled infection.

 2. Chronically uncontrolled hypertension, defined conventionally as consistent systolic
 pressures above 140 or diastolic pressures above 90 despite anti-hypertensive therapy.
 Note that this is NOT a criterion related to particular BP results at the time of
 assessment for eligibility, nor does it apply to acute BP excursions that are related
 to iatrogenic causes, acute pain or other transient, reversible causes.

 3. Requirement for corticosteroids greater than the equivalent of 5 mg of prednisone
 daily.

 4. Poorly controlled diabetes defined by Hemoglobin A1C > 7.0 at screening.

 5. Active or symptomatic viral hepatitis or chronic liver disease.

 6. History of pituitary or adrenal dysfunction.

 7. Clinically significant cardiovascular disease including: a) Myocardial infarction
 within 6 months of Screening visit; b) Uncontrolled angina within 3 months of
 Screening visit; c) Congestive heart failure New York Heart Association (NYHA) class 3
 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the
 past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless
 a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within
 three months of the Screening visit results in a left ventricular ejection fraction
 that is >/= 50%; d) History of clinically significant ventricular arrhythmias (e.g.,
 ventricular tachycardia, ventricular fibrillation, torsade de pointes); e) Prolonged
 corrected QT interval by the Fridericia correction formula (QTcF) on the screening
 Electrocardiogram (ECG) > 470 msec; f) History of Mobitz II second degree or third
 degree heart block without a permanent pacemaker in place;

 8. (Exclusion #7 continued): g) Hypotension (systolic blood pressure < 86 mmHg or
 bradycardia with a heart rate of <50 beats per minute on the Screening ECG, unless
 pharmaceutically induced and thus reversible (i.e. beta blockers).

 9. Other malignancy, except non-melanoma skin cancer, that is active or has a >/= 30%
 probability of recurrence within 12 months.

 10. History of gastrointestinal disorders (medical disorders or extensive surgery) which
 may interfere with the absorption of the study drug.

 11. Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens,
 ketoconazole, or estrogens (5-alpha reductase inhibitors allowed), or LHRH
 agonists/antagonists (*Note: LHRH allowed if begun within 1 month of Day 1). Patients
 having previous or current antiandrogen treatment of greater than 4 weeks in duration
 prior to Cycle 1 Day 1 are eligible with appropriate washout.

 12. Prior systemic treatment with an azole drug within four weeks of Cycle 1 Day1.

 13. Current enrollment in an investigational drug or device study or participation in such
 a study within 30 days of Cycle 1 Day 1.

 14. Allergies, hypersensitivity, or intolerance to prednisone, LHRH analog or excipients
 of prednisone LHRH analog, and abiraterone acetate and enzalutamide.

 15. Previous use of abiraterone acetate or other investigational CYP17 inhibitor (e.g.,
 TAK-700).

 16. Previous investigational antiandrogens (e.g., Enzalutamide, BMS-641988).

 17. Patients receiving anti-coagulant therapy who are unable to stop prior to surgery.

 18. Condition or situation which, in the investigator's opinion, may put the patient at
 significant risk, may confound the study results, or may interfere significantly with
 patient's participation in the study.

 19. Severely compromised immunological state, including being positive for the human
 immunodeficiency virus (HIV).

 20. Patients who are not appropriate surgical candidates for radical prostatectomy based
 on the evaluation of co-existent medical diseases and competing potential causes of
 death (such as but not limited to, unstable angina, myocardial infarction within the
 previous 6 months, or use of ongoing maintenance therapy for life-threatening
 ventricular arrhythmia, uncontrolled hypertension).

 21. Prior chemotherapy, radiation or immune therapy for prostate cancer.

 22. Patients unable to tolerate transrectal ultrasound.

 23. Concomitant therapy with any of the following: a) Chemotherapeutic, biologic, or other
 agents with anti-tumor activity against prostate cancer other than assigned study
 drug; b) Anti-androgens (steroidal or non-steroidal) such as cyproterone acetate,
 flutamide, nilutamide, bicalutamide, etc. other than assigned study drug; c) 5-alpha
 reductase inhibitors such as finasteride, dutasteride, anabolic steroids, etc.; d)
 Estrogens, progestational agents such as megestrol, medroxyprogesterone, DES,
 cyproterone, spironolactone > 50 mg/kg, etc.; e) Androgens such as testosterone,
 dehydroepiandrosterone [DHEA], etc.; f) Ketoconazole; g) Herbal products that may
 decrease PSA levels (e.g., saw palmetto)

 24. Active infection or other medical condition that would make prednisone/ prednisolone
 (corticosteroid) use contraindicated.

 25. Severe hepatic impairment (Child-Pugh Class C).

 26. History of seizure or any condition that may predispose to seizure including, but not
 limited to underlying brain injury, stroke, primary brain tumors, brain metastases, or
 alcoholism. Also, history of loss of consciousness or transient ischemic attack within
 12 months of enrollment (Day 1 visit).

 27. History of significant bleeding disorder unrelated to cancer, including: a) Diagnosed
 congenital bleeding disorders (e.g., von Willebrand's disease); b) Diagnosed acquired
 bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of
 Screening visit; c) History of GI bleeding within 6 months of Screening visit.